eunuchoidism

(redirected from male hypogonadism)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

eunuchoidism

 [u´nŭ-koi-dizm]
hypogonadism in a male; deficiency of the testes or of their secretion, with deficient secondary sex characters.
female eunuchoidism hypogonadism in which the ovaries fail to function at puberty, resulting in infertility, absence of development of secondary sex characteristics, infantile sexual organs, and excessive growth of the long bones.
hypergonadotropic eunuchoidism hypergonadotropic hypogonadism.
hypogonadotropic eunuchoidism hypogonadotropic hypogonadism.

eu·nuch·oid·ism

(yū'nŭ-koyd'izm),
A state in which testes are present but fail to function normally; may be of gonadal or pituitary origin.
Synonym(s): eunuchism (2) , male hypogonadism

eunuchoidism

/eu·nuch·oid·ism/ (u´nik-oi-dizm) hypogonadism in a male; deficiency of the testes or of their secretion, with deficient secondary sex characters.
female eunuchoidism  hypogonadism in which the ovaries fail to function at puberty, resulting in infertility, absence of development of secondary sex characteristics, infantile sexual organs, and excessive growth of the long bones.
hypergonadotropic eunuchoidism  see under hypogonadism.
hypogonadotropic eunuchoidism  see under hypogonadism.

eunuchoidism

[yo̅o̅′nəkoidiz′əm]
a condition resulting from a deficiency in the production or effectiveness of male hormones. The deficiency leads to sterility, abnormal tallness, small testes, and impaired development of secondary sexual characteristics, libido, and sexual potency.

eu·nuch·oid·ism

(yū'nŭ-koyd-izm)
A state in which testes are present but fail to function normally; may be of gonadal or pituitary origin.

eunuchoidism

deficiency of the testes or of their secretion, with impaired sexual power and eunuchoid signs.

hypergonadotropic eunuchoidism
that associated with secretion of high levels of gonadotropins, as in Klinefelter's syndrome.
hypogonadotropic eunuchoidism
that due to lack of gonadotropin secretion.
References in periodicals archive ?
A review of the Male Hypogonadism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Male hypogonadism is most commonly diagnosed through a simple blood test.
Testim 1% testosterone gel for the treatment of male hypogonadism.
Coverage of the Male Hypogonadism pipeline on the basis of route of administration and molecule type.
1 November 2011 - Canada's Trimel Pharmaceuticals Corp (TSX:TRL) on Monday announced first patient enrollment in a phase III trial of its CompleoTRT product intended to treat male hypogonadism.
GlobalData's clinical trial report, Male Hypogonadism Global Clinical Trials Review, H1, 2012" provides data on the Male Hypogonadism clinical trial scenario.
BioSanteos other products include a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) was approved by the FDA on February 14, 2012, which is licensed to Teva Pharmaceuticals USA, Inc.
BioSante's other products include a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) was approved by the FDA on February 14, 2012, which is licensed to Teva Pharmaceuticals, and the Pill-Plus[TM], an oral contraceptive in Phase II clinical development by Pantarhei Bioscience B.
The report provides an in-depth analysis of the major diseases including growth hormone deficiency, acromegaly, male hypogonadism and hypothyroidism.
BioSante's other products include Bio-T-Gel[TM], a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) was approved by the FDA on February 14, 2012, which is licensed to Teva Pharmaceuticals, and the Pill-Plus[TM], an oral contraceptive in Phase II clinical development by Pantarhei Bioscience B.
Bio-T-Gel is a testosterone gel for the treatment of male hypogonadism or low testosterone levels.
BioSante's other products include Bio-T-Gel[TM], a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) is pending, which is licensed to Teva Pharmaceuticals, and the Pill-Plus[TM], an oral contraceptive in Phase II clinical development by Pantarhei Bioscience B.